Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022
March 01 2022 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies for unmet medical needs, today announced that it will
report its fourth quarter and full year 2021 financial and
operating results on Thursday, March 10, 2022, following the close
of the U.S. financial markets. Lineage management will also host a
conference call and webcast on Thursday, March 10, 2022, at 4:30
p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth
quarter and full year 2021 financial and operating results and to
provide a business update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and Canada and should request the
“Lineage Cell Therapeutics Call”. A live webcast of the conference
call will be available online in the Investors section of Lineage’s
website. A replay of the webcast will be available on Lineage’s
website for 30 days and a telephone replay will be available
through March 18, 2022, by dialing (855) 859-2056 from the U.S. and
Canada and (404) 537-3406 from elsewhere outside the U.S. and
Canada and entering conference ID number 7718167.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, which is now being developed under a worldwide
collaboration with Roche and Genentech, a member of the Roche
Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in
Phase 1/2a development for the treatment of acute spinal cord
injuries; and (iii) VAC2, an allogeneic dendritic cell therapy
produced from Lineage’s VAC technology platform for immuno-oncology
and infectious disease, currently in Phase 1 clinical development
for the treatment of non-small cell lung cancer. For more
information, please visit www.lineagecell.com or follow the Company
on Twitter @LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220301005049/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Mike Biega (Mbiega@soleburytrout.com)
(617) 221-9660
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024